Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
AnaptysBio Inc
ANAB | US
58.88
USD7.61
14.84%
ANAB | US
Loading StockChartView...
About AnaptysBio Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
58.88
Open
52.34
High
60.60
Low
49.80
AnaptysBio Inc. a clinical-stage biotechnology company focuses in delivering immunology therapeutics. Its products include Imsidolimab an antibody that inhibits the interleukin-36 receptor which is in the Phase 3 trial for the treatment of generalized pustular psoriasis; Rosnilimab an anti-PD-1 agonist antibody program designed to suppress T-cell driven inflammatory diseases by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; and ANB032 an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences Inc. and changed its name to AnaptysBio Inc. in July 2006. AnaptysBio Inc. was incorporated in 2005 and is based in San Diego California.
View LessANAB | US
Risk
118.6
Sharpe
2.52
Luna's Score
51/100
Recommendation
Hold
Luna says (ANAB | US)
What's Working
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Market Beta (-0.4 to 0.8)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
What's not Working
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Short percentage (> 15%)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
148.3%1 month
118.6%3 months
85.9%6 months
73.8%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
107.54
Debt to equity
38.36
Debt to assets
0.89
Ent. to EBITDA
-1.30
Ent. to rev.
23.91
PEG
-
Other Fundamentals
EBITDA
-154.41M
MarketCap
1.78B
MarketCap(USD)
1.78B
Div. yield
-
Op. margin
-367.52
Erngs. growth
-
Rev. growth
217.10
Ret. on equity
-214.89
Short ratio
21.36
Short perc.
27.02
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
29.30
Range1M
29.30
Range3M
29.30
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
2.10
Price X volume
76.55M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.30 | 0.53 | Cheaper |
| Ent. to Revenue | 23.91 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 107.54 | 15.55 | Expensive |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 85.94 | 72.80 | Par |
| Debt to Equity | 38.36 | -1.23 | Expensive |
| Debt to Assets | 0.89 | 0.25 | Expensive |
| Market Cap | 1.78B | 3.66B | Emerging |
